{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:04:21Z","timestamp":1773770661353,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1097\/wnf.0b013e3181dcda50","type":"journal-article","created":{"date-parts":[[2010,7,27]],"date-time":"2010-07-27T01:29:58Z","timestamp":1280194198000},"page":"169-175","source":"Crossref","is-referenced-by-count":55,"title":["Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia"],"prefix":"10.1097","volume":"33","author":[{"given":"Jaewon","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Myong","family":"Bahk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Sang","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-Whan","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duk-In","family":"Jon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Yeon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan-Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Ku","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Soo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Yeol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Seo","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210203","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00001756-200302100-00023","article-title":"Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice.","volume":"14","author":"Nagai","year":"2003","journal-title":"Neuroreport"},{"key":"R2-1-20210203","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0773.1963.tb01730.x","article-title":"Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain.","volume":"20","author":"Carlsson","year":"1963","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"R3-1-20210203","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R4-1-20210203","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/JCP.0b013e3181692787","article-title":"Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.","volume":"28","author":"Potkin","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R5-1-20210203","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0022-3565(25)38164-4","article-title":"Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocyclooctabpyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and\/or adverse side-effects.","volume":"265","author":"Noda","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R6-1-20210203","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0022-3565(25)10246-2","article-title":"Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.","volume":"264","author":"Oka","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R7-1-20210203","first-page":"135","article-title":"Long-term clinical study of blonanserin for schizophrenia (Japan-wide study).","volume":"11","author":"Kinoshita","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"R8-1-20210203","first-page":"2241","article-title":"Long-term clinical study of blonanserin for schizophrenia (Kanagawa Region Clinical Psychopharmacology Study Group).","volume":"10","author":"Murasaki","year":"2007","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"R9-1-20210203","first-page":"2059","article-title":"Clinical evaluation of blonanserin for schizophrenia: a double-blind trial comparing blonanserin with haloperidol.","volume":"10","author":"Murasaki","year":"2007","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"R11-1-20210203","first-page":"1090","article-title":"Reliability and validity of the Korean version of the Positive and Negative Syndrome Scale.","volume":"40","author":"Yi","year":"2001","journal-title":"J Korean Neuropsychaitr Assoc"},{"key":"R12-1-20210203","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","article-title":"The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.","volume":"23","author":"Garcia","year":"2009","journal-title":"CNS Drugs"},{"key":"R14-1-20210203","first-page":"685","article-title":"Reliability of Korean Brief Psychiatric Rating Scale (BPRS)-comparison of interrater reliability between the two rating methods and correlation of BPRS and Scl-90 self-report test.","volume":"22","author":"Kim","year":"2003","journal-title":"Han'gug Simlihag Hoeji Imsang"},{"key":"R15-1-20210203","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale.","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"R17-1-20210203","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/mds.10255","article-title":"Metric characteristics of the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS): a practical rating scale for drug-induced movement disorders.","volume":"17","author":"Kim","year":"2002","journal-title":"Mov Dis"},{"key":"R18-1-20210203","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.lfs.2004.08.009","article-title":"Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain.","volume":"76","author":"Oka","year":"2004","journal-title":"Life Sci"},{"key":"R19-1-20210203","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.4088\/JCP.v65n1207","article-title":"Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.","volume":"65","author":"Addington","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R20-1-20210203","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jad.2008.12.017","article-title":"The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.","volume":"115","author":"Glick","year":"2009","journal-title":"J Affect Disord"},{"key":"R21-1-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr Res"},{"key":"R22-1-20210203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eurpsy.2005.09.009","article-title":"Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia.","volume":"21","author":"Martin","year":"2006","journal-title":"Eur Psychiatry"},{"key":"R23-1-20210203","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.diabet.2007.01.003","article-title":"Abnormal glucose metabolism in patients treated with antipsychotics.","volume":"33","author":"Scheen","year":"2007","journal-title":"Diabetes Metab"},{"key":"R24-1-20210203","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/10401230600801234","article-title":"Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.","volume":"18","author":"Ramaswamy","year":"2006","journal-title":"Ann Clin Psychiatry"},{"issue":"Suppl 6","key":"R25-1-20210203","first-page":"5","article-title":"Schizophrenia, antipsychotic drugs, and cardiovascular disease.","volume":"66","author":"Glassman","year":"2005","journal-title":"J Clin Psychiatry"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0b013e3181dcda50","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T11:30:41Z","timestamp":1740310241000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201007000-00001"}},"subtitle":["A Randomized, Double-blind, Risperidone-Compared Trial"],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3181dcda50","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}